[
  {
    "ts": null,
    "headline": "Stock Market Today: Small Caps Rise, Edging Dow; Travel Firms Jump On Oil Drop But Byrna, Axon Trip Sell Rules (Live Coverage)",
    "summary": "The Dow Jones Industrial Average gained ground as metal, cyclical and financial stocks kept a bullish profile. But data-center and security software stocks got stung.",
    "url": "https://finnhub.io/api/news?id=64242ecc0962c63a0129754019d45a79127f0238d49c55ecbd07fe6a5e30e84a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752180424,
      "headline": "Stock Market Today: Small Caps Rise, Edging Dow; Travel Firms Jump On Oil Drop But Byrna, Axon Trip Sell Rules (Live Coverage)",
      "id": 135864193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average gained ground as metal, cyclical and financial stocks kept a bullish profile. But data-center and security software stocks got stung.",
      "url": "https://finnhub.io/api/news?id=64242ecc0962c63a0129754019d45a79127f0238d49c55ecbd07fe6a5e30e84a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c360df5e5c17e8be92099f4b5e5d228e79839800bfd9abc6e45aaca2d0a74761",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165300,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 135976881,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c360df5e5c17e8be92099f4b5e5d228e79839800bfd9abc6e45aaca2d0a74761"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Comes Out As ADA Winner",
    "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
    "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165108,
      "headline": "Eli Lilly Comes Out As ADA Winner",
      "id": 135862272,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355656320/image_1355656320.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
      "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865"
    }
  },
  {
    "ts": null,
    "headline": "Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss",
    "summary": "Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss",
    "url": "https://finnhub.io/api/news?id=658649ae1e5c80b79ee3097273c1e2da706ad2cde8ac86134630ecea07af97a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752154010,
      "headline": "Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss",
      "id": 135857654,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=658649ae1e5c80b79ee3097273c1e2da706ad2cde8ac86134630ecea07af97a2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: How To Find And Own America's Greatest Opportunities",
    "summary": "From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.",
    "url": "https://finnhub.io/api/news?id=ea8bddbe307c3f4adbdbbab2dd1e451b04a0dfa24b822126e24eb3a68e548eee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752152408,
      "headline": "Amgen: How To Find And Own America's Greatest Opportunities",
      "id": 135856127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.",
      "url": "https://finnhub.io/api/news?id=ea8bddbe307c3f4adbdbbab2dd1e451b04a0dfa24b822126e24eb3a68e548eee"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
    "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
    "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752138900,
      "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
      "id": 135851366,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1336356688/image_1336356688.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
      "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3"
    }
  },
  {
    "ts": null,
    "headline": "1 Top Dividend Growth Stock to Buy Right Now",
    "summary": "Amgen is dealing with the threat of several fast-approaching patent expirations.  The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels.  Amgen (NASDAQ: AMGN) meets these criteria.",
    "url": "https://finnhub.io/api/news?id=74e1a848168da3f555608155d77f256f84878e72cd0dd106160981b2985446cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752135660,
      "headline": "1 Top Dividend Growth Stock to Buy Right Now",
      "id": 135848200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen is dealing with the threat of several fast-approaching patent expirations.  The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels.  Amgen (NASDAQ: AMGN) meets these criteria.",
      "url": "https://finnhub.io/api/news?id=74e1a848168da3f555608155d77f256f84878e72cd0dd106160981b2985446cd"
    }
  }
]